Table 2.
Effect of P2Y12 inhibitors on frequencies of clinical outcomes in ACS patients.
| Clopidogrel | Prasugrel | Ticagrelor | Cangrelor | |
|---|---|---|---|---|
| Myocardial infarction | ||||
| Clopidogrel | 1.00 | 0.75 (0.63–0.89) | 0.88 (0.72–1.08) | 0.94 (0.78–1.13) |
| Prasugrel | 1.33 (1.12–1.58) | 1.00 | 1.17 (0.93–1.48) | 1.25 (0.97–1.61) |
| Ticagrelor | 1.13 (0.92–1.39) | 0.85 (0.67–1.07) | 1.00 | 1.06 (0.80–1.40) |
| Cangrelor | 1.07 (0.88–1.29) | 0.80 (0.62–1.04) | 0.94 (0.71–1.24) | 1.00 |
| Stroke | ||||
| Clopidogrel | 1.00 | 0.96 (0.74–1.23) | 1.10 (0.88–1.36) | 1.08 (0.49–2.37) |
| Prasugrel | 1.05 (0.81–1.35) | 1.00 | 1.15 (0.85–1.55) | 1.13 (0.49–2.59) |
| Ticagrelor | 0.91(0.74–1.13) | 0.87 (0.64–1.18) | 1.00 | 0.98 (0.43–2.23) |
| Cangrelor | 0.93 (0.42–2.05) | 0.89 (0.39–2.04) | 1.02 (0.45–2.31) | 1.00 |
| Cardiovascular mortality | ||||
| Clopidogrel | 1.00 | 0.85 (0.75–0.97) | 0.82 (0.73–0.93) | 1.00 (0.52–1.92) |
| Prasugrel | 1.17 (1.03–1.34) | 1.00 | 0.97 (0.83–1.13) | 1.17 (0.60–2.29) |
| Ticagrelor | 1.21 (1.08–1.37) | 1.03 (0.89–1.21) | 1.00 | 1.21 (0.62–2.36) |
| Cangrelor | 1.00 (0.52–1.92) | 0.85 (0.44–1.66) | 0.82 (0.42–1.60) | 1.00 |
| MACE | ||||
| Clopidogrel | 1.00 | 0.80 (0.69–0.94) | 0.89 (0.75–1.05) | 0.90 (0.75–1.07) |
| Prasugrel | 1.25 (1.07–1.46) | 1.00 | 1.10 (0.91–1.34) | 1.12 (0.88–1.42) |
| Ticagrelor | 1.13 (0.95–1.34) | 0.91 (0.75–1.10) | 1.00 | 1.01 (0.79–1.30) |
| Cangrelor | 1.12 (0.93–1.34) | 0.89 (0.70–1.14) | 0.99 (0.77–1.27) | 1.00 |
| Definite or probable stent thrombosis | ||||
| Clopidogrel | 1.00 | 0.49 (0.38–0.63) | 0.72 (0.57–0.90) | 0.59 (0.43–0.81) |
| Prasugrel | 2.03 (1.58–2.62) | 1.00 | 1.46 (1.08–1.97) | 1.20 (0.80–1.81) |
| Ticagrelor | 1.39 (1.12–1.74) | 0.69 (0.51–0.93) | 1.00 | 0.83 (0.56–1.22) |
| Cangrelor | 1.69 (1.23–2.32) | 0.83 (0.55–1.25) | 1.21 (0.82–1.78) | 1.00 |
| All-cause mortality | ||||
| Clopidogrel | 1.00 | 0.91 (0.76–1.09) | 0.88 (0.73–1.05) | 0.75 (0.46–1.22) |
| Prasugrel | 1.10 (0.92–1.32) | 1.00 | 0.97 (0.78–1.20) | 0.83 (0.50–1.38) |
| Ticagrelor | 1.14 (0.95–1.37) | 1.03 (0.83–1.28) | 1.00 | 0.86 (0.51–1.43) |
| Cangrelor | 1.33 (0.82–2.15) | 1.21 (0.72–2.02) | 1.17 (0.70–1.95) | 1.00 |
Results are the Odds Ratios (95% Confidence Interval) in the column-defining therapy compared with the Odds Ratios in the row-defining therapy. For efficacy and safety, Odds Ratio < 1 favors the column-defining therapy. Significant results are shown in bold.
ACS acute coronary syndrome, MACE major cardiovascular events.